now pay attention to this
"analogous erythropoiesis-stimulating agents (ESAs)"
behave like rhEPO, as CERA is one of the many ESA's, and look at this from the end of the paper i just posted
"Another strategy has been to replace recombinant ESAs by Epo mimetic peptides (EMPs), synthetic cyclic peptides of about 20 amino acids. EMPs show no sequence homology to Epo but signal through the EpoR (fig. (fig.2).2). As the first EMP, peginesatide (Omontys®; Affymax/Takeda) was approved in the USA in 2012 for SC or IV treatment of CKD patients on dialysis. However, the drug was recalled early in 2013, since 0.2% of patients experienced serious and 0.02% of patients experienced fatal hypersensitivity reactions. In an alternative approach, EMPs have been constructed onto human IgG-based scaffolds by recombinant DNA technology. The seminal compound, CNTO 528 (Centocor), increased Hb concentration on IV administration in a phase I clinical trial. The follow-on product CNTO 530, a dimeric EMP fused to a human IgG4 Fc scaffold, was shown to expand the pool of erythrocytic progenitors in vitro and in vivo. However, doubt may be raised as to the advantages of this type of biopharmaceutical over the established ESAs."
so since 2012, there are now EMP's and also ORAL ESA's...but no worries its all myth and placebo on what it can do for athletes.